Toripalimab for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study is looking at how well the drug toripalimab works in people with extensive-stage small cell lung cancer when it's the first treatment they receive. It's a real-world study, meaning it observes what happens in everyday medical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of extensive-stage small cell lung cancer
- Your doctor has decided to start treatment with toripalimab (an immunotherapy drug) as your first therapy
- You must be willing to sign a consent form and have your medical records available during the study
- You cannot be pregnant or breastfeeding
- You must not have a known severe allergy to anti-PD-1 antibody drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab) and chemotherapy for people with advanced small cell lung cancer that has progressed after previous treatments. It aims to see if this combination can help control the cancer.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This study tests a new drug (BL0020) combined with an immunotherapy drug (toripalimab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
This trial tests whether giving an immunotherapy drug called toripalimab together with chemotherapy after lung cancer surgery can help prevent small cell lung cancer from coming back. It is for people who had surgery to remove lung cancer and were found to have small cell lung cancer in the removed tissue.
This study tests whether a combination of two targeted drugs can help keep extensive-stage small cell lung cancer from growing after initial treatment. The goal is to see if this maintenance approach extends the time before the cancer worsens.
Hear when a new Toripalimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.